In the BELLE-3 trial, the combination of buparlisib with fulvestrant was not recommended in postmenopausal, hormone receptor (HR)-positive, HER2-negative, advanced breast cancer for the safety profile [138]. Here, ERBB2 is linked to breast carcinoma.